In this review:
Real-world treatment in mHSPC
Nivolumab + rucaparib for chemotherapy-naive mCRPC
Patient-reported outcomes after PSMA-targeted radionuclide therapy
Enoblituzumab for localised prostate cancer
Oestrogen receptor subtype expression in prostate cancer
PRIMORDIUM in PSMA-PET-positive HSPC
ADT, stereotactic radiotherapy plus anti-PD-L1 immunotherapy for mHSPC
Talazoparib in mCRPC with DNA damage response alterations
Please login below to download this issue (PDF)